Therapeutic Goods Regulations (Amendment)

Overview

Statutory Rules 1975 No. 36, made under the Therapeutic Goods Act 1966-1973, was enacted to amend the Therapeutic Goods Regulations by introducing changes to the composition of the Therapeutic Goods Advisory Committee. This amendment was introduced to address the need for more diverse expertise within the committee, ensuring it is better equipped to provide informed advice on therapeutic goods regulation. The regulation was enacted by the Governor-General, John R. Kerr, on the advice of the Executive Council, with the objective of enhancing the expertise and representation within the Therapeutic Goods Advisory Committee, thereby improving the regulatory framework for therapeutic goods in Australia. This legislative instrument was designed to ensure that the committee includes representatives from relevant professional bodies, such as The Society of Hospital Pharmacists of Australia, thus addressing a gap in the previous regulatory structure.

Scope and Application

Statutory Rules 1975 No. 36, made under the Therapeutic Goods Act 1966-1973, serves to amend the Therapeutic Goods Regulations, specifically targeting the composition of the Therapeutic Goods Advisory Committee. The regulation applies to the Therapeutic Goods Advisory Committee, impacting the process by which members are appointed to this committee. The amendment allows for a person to be appointed by the Minister on the nomination of The Society of Hospital Pharmacists of Australia, thereby extending the scope of who can be included in the committee. This change broadens the committee's representation and ensures it encompasses a broader spectrum of expertise, particularly in hospital pharmacy. The regulation operates within the Commonwealth jurisdiction, impacting the operations and recommendations of the Therapeutic Goods Advisory Committee on a national level. The regulation does not explicitly exclude any persons, entities, or conduct but rather extends the criteria for inclusion in the committee, thereby indirectly shaping the committee's overall composition and advisory capacity.

Key Provisions

The main operative sections of these regulations, particularly Regulation 17, involve amendments to the composition of the Therapeutic Goods Advisory Committee (TGAC) under the Therapeutic Goods Act 1966-1973. Regulation 17(2)(f) is altered to omit the word “and” and to add a new appointment criterion, allowing a member to be nominated by The Society of Hospital Pharmacists of Australia and appointed by the Minister (Regulation 17(2)(h)). This change expands the scope of professional representation on the TGAC by including a representative from the Society of Hospital Pharmacists of Australia. These regulations impose obligations on the Minister for Health to ensure that the TGAC includes a member appointed on the nomination of The Society of Hospital Pharmacists of Australia. This requirement ensures that the committee reflects a broader range of professional perspectives, particularly those relevant to hospital pharmacy, in its deliberations and recommendations concerning therapeutic goods. The Minister must act on the nomination provided by the Society, thereby incorporating its suggested candidate into the committee’s membership. Failure to comply with these regulations could potentially lead to legal consequences, although the specific penalties are not detailed within the statutory rules. Given the context of therapeutic goods regulation and the importance of expert advice, non-compliance might result in administrative or judicial review, with possible implications for the approval and regulation of therapeutic goods. The absence of explicit penalties in these rules suggests that enforcement might be pursued through the broader legislative framework under which these regulations operate.